HER2 AS A GENOMIC PREDICTOR IN HER2+ BREAST CANCER - Banco de Patentes
Back HER2 AS A GENOMIC PREDICTOR IN HER2+ BREAST CANCER
HER2 AS A GENOMIC PREDICTOR IN HER2+ BREAST CANCER
The present invention allows predicting the degree of efficacy of different therapies in HER2+ breast cancer patients. The method uses an in vitro marker that helps the oncologist decide the most appropriate therapy, and particularly in the possibility of avoiding chemotherapy in the early stages of this disease.
The technology has been filed under patent application to the European Patent Office, with priority date 07/12/2016, adn in co-ownership with the Vall d'Hebron Institute of Oncology Private Foundation, SOLTI Foundation and Hospital Clínic de barcelona.
Antonio Llombart Cussac
Jefe del Servicio de Oncología
Hospital Arnau de Vilanova
Tel: +34963987700
E-mail:allombart1@yahoo.com
Area de Innovación
FISABIO
Avda. Catalunya, 21
46010 - Valencia
Tel: +34961926351
E-mail: innovacion_fisabio@gva.es
Web: www.fisabio.es